<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00162</title>
	</head>
	<body>
		<main>
			<p><!-- PJG 0012 frnewline -->  <!-- PJG FTAG 4717 -->  <!-- PJG STAG 4717 -->  <!-- PJG ITAG l=01 g=1 f=1 --> Tuesday <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=02 g=1 f=1 --> July 5, 1994 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=1 --> Part IV <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Department of Health and Human Services <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> National Institutes of Health <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> Guidelines for Research Involving Recombinant DNA Molecules (NIH  <!-- PJG 0012 frnewline --> Guidelines); Notice <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG -->  <!-- PJG FTAG 4701 -->  <!-- PJG STAG 4701 -->  <!-- PJG ITAG l=90 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=1 --> &blank;/&blank;Vol. 59, No. 127&blank;/&blank;Tuesday, July 5,  <!-- PJG 0012 frnewline --> 1994&blank;/&blank;Notices <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES </USDEPT>  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=44 g=1 f=1 --> June 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> These NIH Guidelines supersede all earlier versions and shall be in effect until further notice.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> Table of Contents  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> Section I. Scope of the NIH Guidelines  <!-- PJG 0012 frnewline --> Section I&hyph;A. Purpose  <!-- PJG 0012 frnewline --> Section I&hyph;B. Definition of Recombinant DNA Molecules  <!-- PJG 0012 frnewline --> Section I&hyph;C. General Applicability  <!-- PJG 0012 frnewline --> Section I&hyph;D. General Definitions  <!-- PJG 0012 frnewline --> Section II. Containment  <!-- PJG 0012 frnewline --> Section III. Experiments Covered by the NIH Guidelines  <!-- PJG 0012 frnewline --> Section III&hyph;A. Experiments that Require Institutional Biosafety Committee Approval, RAC Review, and NIH Approval Before Initiation  <!-- PJG 0012 frnewline --> Section III&hyph;B. Experiments that Require NIH/ORDA and Institutional Biosafety Committee Approval Before Initiation  <!-- PJG 0012 frnewline --> Section III&hyph;B&hyph;1. Experiments Involving the Cloning of Toxin Molecules with LD <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=2 --> 50 <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  of Less than 100 Nanograms Per Kilogram Body Weight  <!-- PJG 0012 frnewline --> Section III&hyph;B&hyph;2. Accelerated Review of Human Gene Transfer Experiments  <!-- PJG 0012 frnewline --> Section III&hyph;B&hyph;3. Minor Modifications to Human Gene Transfer Experiments  <!-- PJG 0012 frnewline --> Section III&hyph;C. Experiments that Require Institutional Biosafety Committee  <!-- PJG 0012 frnewline --> Approval Before Initiation  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;1. Experiments Using Human or Animal Pathogens (Class 2, Class 3, Class 4, or Class 5) Agents as Host-Vector Systems  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;2. Experiments in which DNA from Human or Animal Pathogens (Class 2, Class 3, Class 4, or Class 5) Agents is Cloned into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;3. Experiments Involving the Use of Infectious Animal or Plant DNA or RNA Viruses or Defective Animal or Plant DNA or RNA Viruses in the Presence of Helper Virus in Tissue Culture Systems  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;4. Experiments Involving Whole Animals  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;5. Experiments Involving Whole Plants  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;6. Experiments Involving More than 10 Liters of Culture  <!-- PJG 0012 frnewline --> Section III&hyph;C&hyph;7. Human Gene Transfer Experiments Not Covered by Section III&hyph;A&hyph;2, III&hyph;B&hyph;2, III&hyph;B&hyph;3, and Not Considered Exempt under Section V&hyph;U  <!-- PJG 0012 frnewline --> Section III&hyph;D. Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation  <!-- PJG 0012 frnewline --> Section III&hyph;D&hyph;1. Experiments Involving the Formation of Recombinant DNA Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus  <!-- PJG 0012 frnewline --> Section III&hyph;D&hyph;2. Experiments Involving Whole Plants  <!-- PJG 0012 frnewline --> Section III&hyph;E. Exempt Experiments  <!-- PJG 0012 frnewline --> Section IV. Roles and Responsibilities  <!-- PJG 0012 frnewline --> Section IV&hyph;A. Policy  <!-- PJG 0012 frnewline --> Section IV&hyph;B. Responsibilities of the Institution  <!-- PJG 0012 frnewline --> Section IV&hyph;B&hyph;1. General Information  <!-- PJG 0012 frnewline --> Section IV&hyph;B&hyph;2. Institutional Biosafety Committee (IBC)  <!-- PJG 0012 frnewline --> Section IV&hyph;B&hyph;3. Biological Safety Officer (BSO)  <!-- PJG 0012 frnewline --> Section IV&hyph;B&hyph;4. Principal Investigator (PI)  <!-- PJG 0012 frnewline --> Section IV&hyph;C. Responsibilities of the National Institutes of Health (NIH)  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1. NIH Director  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;a. General Responsibilities  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b. Specific Responsibilities  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1). Major Actions  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2). Minor Actions  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;2. Recombinant DNA Advisory Committee (RAC)  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;3. Office of Recombinant DNA Activities (ORDA)  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;4. Other NIH Components  <!-- PJG 0012 frnewline --> Section IV&hyph;D. Compliance with the NIH Guidelines  <!-- PJG 0012 frnewline --> Section IV&hyph;E. Voluntary Compliance  <!-- PJG 0012 frnewline --> Section V. Footnotes and References of Sections I&hyph;IV  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG --></p>
		</main>
</body></html>
            